Robert Cobuzzi

Robert Cobuzzi is a Venture Partner at Sunstone Life Science Ventures. Robert has over 25 years of experience in the life sciences industry, with a focus on rare and ultra-rare pediatric mitochondrial diseases. Prior to joining Sunstone, Robert served as the President of Endo Pharmaceuticals from January 2005 to February 2018. From January 2001 to December 2005, they were the Clinical Program Director/Director of Scientific Licensing at Adolor Corporation. From January 1999 to December 2001, they were the Manager of Worldwide Regulatory Affairs at Centocor. In July 2019, they founded MitoCUREia, Inc., a company based upon research at the Children's Hospital of Philadelphia (CHOP) to develop advanced diagnostics and innovative therapies to optimize the bioenergetic health of people living with Mitochondrial Diseases. Robert served as the President and CEO of MitoCUREia from July 2019 to July 2020. Robert has also served as an Advisor for the Mitochondrial Medicine Frontier Program at Children's Hospital of Philadelphia from January 2019 to April 2020, and as a Member of the Business Development Board at Sunstone Capital from January 2010 to March 2019. Prior to their work in the pharmaceutical industry, they were a Clinical Program Scientist/Manager at AstraMerck from January 1995 to December 1999.

They work with Merete Lundbye Møller - Venture Partner, General Counsel, Claus Andersson - General Partner, and Jacob Lange Moresco - Investment Director. Robert Cobuzzi reports to Søren Lemonius, Managing General Partner.